title: Melatonin overcomes resistance to clofarabine in two leukemic cell lines by increased expression of deoxycytidine kinase.
abstract: Drug resistance remains a serious problem in leukemia therapy. Among newly developed nucleoside antimetabolites, clofarabine has broad cytotoxic activity showing therapeutic promise and is currently approved for relapsed acute lymphoblastic leukemia. To investigate the mechanisms responsible for clofarabine resistance, we established two clofarabine-resistant lymphoblastic leukemia cell lines from parental lines. To elucidate the mechanisms against clofarabine resistance in two newly established clofarabine-resistant cell lines, we measured the expression of export pumps multidrug resistance protein 1, multidrug resistance-associated protein 1, and ATP-binding cassette subfamily G member 2. There were no differences in the expression between clofarabine-sensitive and -resistant cell lines. Next, we determined expression of deoxycytidine kinase (dCK), which phosphorylates clofarabine to exert cytotoxicity, in clofarabine-sensitive and -resistant cells. Clofarabine-resistant cells showed significantly decreased expression of dCK RNA when compared with sensitive cells. To elucidate the mechanisms of decreased dCK expression in clofarabine-resistant cells, we analyzed the methylation status of CpG islands of the dCK promoter and found no differences in methylation status between clofarabine-sensitive and -resistant cells. Next, we measured the acetylation status of histone and found that total histone acetylation, and histone H3 and H4 acetylation on chromatin immunoprecipitation assay were significantly decreased in resistant cells. Melatonin is an indolamine that functions in the regulation of chronobiological rhythms to exert cytotoxic effects. We examined the effects of melatonin in clofarabine-resistant cells and found that melatonin treatment led to significantly increased cytotoxicity with clofarabine in resistant cells via increased acetylation. Melatonin may be a useful candidate for overcoming clofarabine resistance in two newly established clofarabine resistant leukemia cell lines.
authors.affiliation: Department of Pediatrics, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
authors.forename: Miho
authors.initials: M
authors.lastname: Yamanishi
authors.affiliation: Department of Pediatrics, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
authors.forename: Hidehiko
authors.initials: H
authors.lastname: Narazaki
authors.affiliation: Department of Pediatrics, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Electronic address: VFF13540@nifty.ne.jp.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Asano
mesh_terms: D000227:Adenine Nucleotides / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001087:Arabinonucleosides / Q000627:therapeutic use; D045744:Cell Line, Tumor; D000077866:Clofarabine; D003842:Deoxycytidine Kinase / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005434:Flow Cytometry; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D006801:Humans; D020128:Inhibitory Concentration 50; D007938:Leukemia / Q000188:drug therapy*; D008550:Melatonin / Q000494:pharmacology*; D060888:Real-Time Polymerase Chain Reaction
chemical_list: D000227:Adenine Nucleotides; D000970:Antineoplastic Agents; D001087:Arabinonucleosides; D000077866:Clofarabine; D003842:Deoxycytidine Kinase; D008550:Melatonin